Results 31 to 40 of about 3,186 (203)

Fototerapia en el prurigo nodular. Experiencia propia y revisión de la literatura

open access: yesActas Dermo-Sifiliográficas, 2021
Resumen: Antecedentes y objetivo: El prurigo nodular (PN) es una dermatosis inflamatoria crónica caracterizada por la presencia de lesiones nodulares, intensamente pruriginosas, con gran impacto en la calidad de vida. El intenso prurito y el rascado son
A. Arrieta   +4 more
doaj   +1 more source

Increased β‐endorphin and autotaxin in patients with prurigo

open access: yesJournal of Cutaneous Immunology and Allergy, 2019
Objectives Prurigo is a treatment‐resistant inflammatory disease of unknown etiology. Persistent and severe itch is a major and important clinical symptom, but pathological mechanisms and/or actual mediators for itch in prurigo remain to be defined ...
Takahiro Ishikawa   +4 more
doaj   +1 more source

Case Report: Pemphigoid Nodularis—Five Patients With Many Years of Follow-Up and Review of the Literature

open access: yesFrontiers in Immunology, 2022
Pemphigoid nodularis is a rare form of pemphigoid that joins the clinical picture of prurigo nodularis and the immunological features of bullous pemphigoid, which is therapeutically challenging.
Konrad Szymanski   +5 more
doaj   +1 more source

Biopsychosocial factors associated with prurigo nodularis in endogenous eczema

open access: yesIndian Journal of Dermatology, 2015
Background: Prurigo nodularis is a dermatological manifestation secondary to chronic scratching or picking on focal areas of the skin. Its pathogenesis remains poorly understood, and limited data has indicated its association with psychological factors ...
Choon Chiat Oh   +3 more
doaj   +1 more source

Dupilumab for the treatment of prurigo nodularis: A systematic review

open access: yesFrontiers in Immunology, 2023
BackgroundConventional treatment techniques have limited efficacy and more side effects in the treatment of prurigo nodularis. The better alternative treatment option for better outcomes of the disease is dupilumab.ObjectiveThe objective of this study ...
Peng Cao   +6 more
doaj   +1 more source

Successful treatment of eosinophilic esophagitis with upadacitinib prescribed for atopic dermatitis

open access: yesJPGN Reports, EarlyView.
Abstract We describe a pediatric patient treated with upadacitinib for atopic dermatitis (AD) who subsequently achieved sustained clinical and histologic remission of eosinophilic esophagitis (EoE). Upadacitinib is an oral small molecule selective Janus kinase 1 inhibitor that inhibits janus kinase‐signal transduction and activation of transcription ...
Nathalie Nguyen, Maureen Bauer
wiley   +1 more source

Prurigo nodularis after acupuncture [PDF]

open access: yesJAAD Case Reports, 2015
Prurigo nodularis (PN) is a difficult-to-treat, chronic skin disorder characterized by the eruption of pruritic, hyperkeratotic nodules of the extensor surfaces.1 Here, we describe a patient who presented to our clinic with symptomatic, biopsy-proven PN shortly after acupuncture therapy.
Almazan, Timothy Hermosura   +1 more
openaire   +2 more sources

Successful Treatment of Severe Adult Linear IgA Dermatosis Using Dupilumab

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Linear IgA dermatosis (LAD) is a rare autoimmune subepidermal bullous dermatosis, characterised by the presence of erythematous vesiculobullous lesions arranged in rosettes or herpetiform clusters. The standard treatment involves the administration of dapsone, followed by sulfasalazine, and general corticosteroid therapy, often in combination ...
Célia Delesalle   +7 more
wiley   +1 more source

Recurrent prurigo nodularis related to infected tonsils: a case report

open access: yesJournal of Medical Case Reports, 2008
Introduction Prurigo nodularis is an unusual disorder of unknown aetiology, which is notoriously resistant to therapy, and is characterized by extremely pruritic nodules with well-defined clinical symptoms and histopathological findings.
Katotomichelakis Michael   +5 more
doaj   +1 more source

Home - About - Disclaimer - Privacy